Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted withdrawal of therapy in juvenile idiopathic arthritis remission
2013-003956-18Phase 4Active
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methotrexate, etanercept, adalimumab and abatacept in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Comparison of flare rates between therapy withdrawal and maintenance therapy groups and Dynamic biomarker-guided stratification using S100A12/hsCRP. Started Jan 2014; status: active.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2013-003956-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003956-18.